Area of research
Developmental Neuroscience · Genetics
Research interest
Research interests include Neurogenesis and neuroplasticity mechanisms, Glioma Diagnosis and Treatment, Epigenetics and DNA Methylation, and Cancer, Hypoxia, and Metabolism.
Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
Author response: Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival
Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer
A Neuroethics Backbone for the Evolving Canadian Brain Research Strategy
Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
The Functional Genomic Circuitry of Human Glioblastoma Stem Cells
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i>
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma
Brain tumour cells interconnect to a functional and resistant network
<i>IDH1</i> Mutation Induces Reprogramming of Pyruvate Metabolism
Novel <i>MSH6</i> Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation
Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells <i>In Vitro</i> and <i>In Vivo</i> and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
BRAIN TUMOUR INITIATING CELLS AND TARGETING STAT3 ONCOGENIC SIGNALLING IN GBM
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation